BioSpace News Archive

FIRE1 Raises $50M Series C

The financing provides FIRE1 with capital to further advance its novel remote monitoring solution to improve outcomes for heart failure patients.

January 30, 2018
·
6 min read
Deals

Eyenovia Announces Closing of $27.3M Initial Public Offering

Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services and Roth Capital Partners acted as joint book-running managers for the offering.

January 30, 2018
·
2 min read
Biotech Bay

Five Prime Therapeutics Announces Closing of Upsized Public Offering

Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Leerink Partners LLC are acting as book-running managers for the offering.

January 30, 2018
·
1 min read
Biotech Bay

Iovance Biotherapeutics Announces Closing of $172.5M Common Stock Public Offering

Iovance intends to use the proceeds from this offering to fund its ongoing clinical trials for its current product candidates, including its ongoing Phase 2 clinical trials of LN-144,

January 30, 2018
·
4 min read
Business

University of Iowa Health Care Increases Industry-Sponsored Clinical Trial Opportunities With TriNetX

In the first six months, UI Health Care was provided access to over 40 clinical trial opportunities from biopharmaceutical companies and CROs on the network.

January 30, 2018
·
3 min read
Drug Development

Diffusion Pharmaceuticals Announces First Patient Dosed in Phase III Trial With TSC in Inoperable Glioblastoma Multiforme

The INTACT trial will compare standard of care radiation therapy and chemotherapy plus TSC against SOC alone.

January 30, 2018
·
10 min read
Policy

TriNetX Achieves ISO 27001:2013 Certification

The certification reinforces TriNetX’s dedication to conducting best practices and its determination to provide the highest level of information security for its clients.

January 30, 2018
·
2 min read
Revive Therapeutics Advances Research Program of Cannabinoid-Based Therapies Targeting Liver Diseases

The research will be overseen by Sanyal Biotechnology LLC (“SanyalBio”), the Company’s strategic research partner for liver diseases.

January 30, 2018
·
7 min read
GN Store Nord: Transactions in Relation to Share Buyback Program - Jan. 30, 2018

The share buyback program has been initiated in order to reduce the company’s share capital and to cover obligations under the long-term incentive program.

January 30, 2018
·
2 min read
Vaxil Completes Oversubscribed Financing to Advance its Cancer Immunotherapy Research and Development

Vaxil Bio is pleased to announce the closing of an oversubscribed equity financing of $1,810,000.

January 30, 2018
·
6 min read